Unknown

Dataset Information

0

MerTK as a therapeutic target in glioblastoma.


ABSTRACT:

Background

Glioma-associated macrophages and microglia (GAMs) are components of the glioblastoma (GBM) microenvironment that express MerTK, a receptor tyrosine kinase that triggers efferocytosis and can suppress innate immune responses. The aim of the study was to define MerTK as a therapeutic target using an orally bioavailable inhibitor, UNC2025.

Methods

We examined MerTK expression in tumor cells and macrophages in matched patient GBM samples by double-label immunohistochemistry. UNC2025-induced MerTK inhibition was studied in vitro and in vivo.

Results

MerTK/CD68+ macrophages increased in recurrent tumors while MerTK/glial fibrillary acidic protein-positive tumor cells did not. Pharmacokinetic studies showed high tumor exposures of UNC2025 in a syngeneic orthotopic allograft mouse GBM model. The same model mice were randomized to receive vehicle, daily UNC2025, fractionated external beam radiotherapy (XRT), or UNC2025/XRT. Although median survival (21, 22, 35, and 35 days, respectively) was equivalent with or without UNC2025, bioluminescence imaging (BLI) showed significant growth delay with XRT/UNC2025 treatment and complete responses in 19%. The responders remained alive for 60 days and showed regression to 1%-10% of pretreatment BLI tumor burden; 5 of 6 were tumor free by histology. In contrast, only 2% of 98 GBM mice of the same model treated with XRT survived 50 days and none survived 60 days. UNC2025 also reduced CD206+ macrophages in mouse tumor samples.

Conclusions

These results suggest that MerTK inhibition combined with XRT has a therapeutic effect in a subset of GBM. Further mechanistic studies are warranted.

SUBMITTER: Wu J 

PROVIDER: S-EPMC5761530 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Glioma-associated macrophages and microglia (GAMs) are components of the glioblastoma (GBM) microenvironment that express MerTK, a receptor tyrosine kinase that triggers efferocytosis and can suppress innate immune responses. The aim of the study was to define MerTK as a therapeutic target using an orally bioavailable inhibitor, UNC2025.<h4>Methods</h4>We examined MerTK expression in tumor cells and macrophages in matched patient GBM samples by double-label immunohistochemistr  ...[more]

Similar Datasets

| S-EPMC4012720 | biostudies-literature
| S-EPMC5722512 | biostudies-literature
| S-EPMC11352666 | biostudies-literature
| S-EPMC3639697 | biostudies-literature
| S-EPMC5078043 | biostudies-literature
| S-EPMC6049871 | biostudies-other
| S-EPMC4480757 | biostudies-literature
| S-EPMC5346667 | biostudies-literature
| S-EPMC8395085 | biostudies-literature
| S-EPMC9266903 | biostudies-literature